Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carregado – page 5

669 clinical trials in Carregado, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carregado at a glance
669
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

669 trials in Carregado

Open in trial search

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:JX10
  • Sponsor:Corxel Pharmaceuticals Co. Ltd.

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

HIV infection

Recruiting

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study of subcutaneous anifrolumab pharmacokinetics, pharmacodynamics and safety in children aged 5 to <18 years with systemic lupus erythematosus

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carregado

What the registry says about research in the country

01 Nephrology Research

Research focusing on secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. Clinical studies aim to evaluate new therapeutic approaches for managing hormone levels in patients with end-stage kidney disease (ESKD).

  • Hormone regulation in dialysis patients
  • SHPT treatment optimization
  • Renal replacement therapy outcomes

Studies evaluate novel treatments' efficacy in reducing parathyroid hormone levels in dialysis patients.

02 Cardiovascular Research

Investigations into atherosclerotic cardiovascular disease among dialysis patients, with particular focus on inflammatory markers. Studies examine the relationship between kidney disease and cardiovascular complications.

  • Cardiovascular outcomes in ESKD
  • Inflammatory biomarkers
  • Dialysis-related cardiovascular complications

Research aims to assess new treatments targeting inflammation in dialysis patients with cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.